Advertisement

The Relevance of Normal-Appearing White Matter Pathology in Multiple Sclerosis

  • M. MacInnes
  • D. L. Arnold
Chapter
Part of the Topics in Neuroscience book series (TOPNEURO)

Abstract

Although the current dogma is that multiple sclerosis (MS) is a T-cell-mediated inflammatory demyelinating disease, a number of studies have provided evidence to challenge this concept. Data obtained through the use of MR techniques such as magnetic resonance spectroscopy (MRS) and magnetization transfer imaging support the argument that MS could be primarily a degenerative disease in which focal inflammatory lesions occur secondarily. This chapter will focus on some of the evidence that supports this concept.

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Magnetic Resonance Spectroscopy Expand Disability Status Scale Magnetization Transfer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37–45PubMedCrossRefGoogle Scholar
  2. 2.
    Dautry C, Vaufrey F, Brouillet E et al (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789–799PubMedCrossRefGoogle Scholar
  3. 3.
    Fu L, Matthews PM, De Stefano N et al (1998) Imaging axonal damage of normal- appearing white matter in multiple sclerosis. Brain 121:103–113PubMedCrossRefGoogle Scholar
  4. 4.
    Kapeller P, McLean MA, Griffin CM et al (2001) Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 248:131–138PubMedCrossRefGoogle Scholar
  5. 5.
    De Stefano N, Narayanan S, Francis S et al (2002) Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59:1565–1571PubMedCrossRefGoogle Scholar
  6. 6.
    Filippi M, Bozzali M, Rovaris M et al (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433–437PubMedCrossRefGoogle Scholar
  7. 7.
    Dousset V, Grossman RI, Ramer KN et al (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182:483–491PubMedGoogle Scholar
  8. 8.
    Pike GB, De Stefano N, Narayanan S et al (1999) Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 20:829–837PubMedGoogle Scholar
  9. 9.
    Tartaglia MC, Narayanan S, De Stefano N et al (2002) Choline is increased in prelesional normal appearing white matter in multiple sclerosis. J Neurol 249:1382–1390PubMedCrossRefGoogle Scholar
  10. 10.
    Arnold DL, Matthews PM, Francis GS et al (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31:235–241PubMedCrossRefGoogle Scholar
  11. 11.
    Laule C, Vavasour IM, Whittall KP et al (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250:924–931PubMedCrossRefGoogle Scholar
  12. 12.
    Rocca MA, Cercignani M, Iannucci G et al (2000) Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology 55:882–884PubMedCrossRefGoogle Scholar
  13. 13.
    Wuerfel J, Bellmann-Strobl J, Brunecker P et al (2004) Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127:111–119PubMedCrossRefGoogle Scholar
  14. 14.
    Wolinsky J, Narayana P, Fenstermacher M (1990) Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 40:1764–1769PubMedCrossRefGoogle Scholar
  15. 15.
    Miller DH, Barkhof F, Frank JA et al (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676–1695PubMedCrossRefGoogle Scholar
  16. 16.
    Trapp BD, Bö L, Mork S, Chang A (1999) Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98:49–56PubMedCrossRefGoogle Scholar
  17. 17.
    De Stefano N, Iannucci G, Sormani MP et al (2002) MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 249:1072–1077PubMedCrossRefGoogle Scholar
  18. 18.
    Brex PA, Jenkins R, Fox NC et al (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689–1691PubMedCrossRefGoogle Scholar
  19. 19.
    Dalton CM, Brex PA, Jenkins R et al (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141–147PubMedCrossRefGoogle Scholar
  20. 20.
    Molyneux PD, Kappos L, Polman C et al (2000) The effect of interferon beta- lb treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256–2263PubMedCrossRefGoogle Scholar
  21. 21.
    Filippi M, Rovaris M, Iannucci G et al (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55:1714–1718PubMedCrossRefGoogle Scholar
  22. 22.
    Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438PubMedCrossRefGoogle Scholar
  23. 23.
    Goodkin DE (2000) The North American Study Group on Interferon (β-lb in Secondary Progressive MS. Interferon (3–1b in secondary progressive multiple sclero- sis: clinical and MRI results of a 3-year randomized controlled trial. Neurology 54 (suppl):2352 [Abstract]Google Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • M. MacInnes
  • D. L. Arnold

There are no affiliations available

Personalised recommendations